drugset / Trial / NCT01651481

Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination

NCT01651481

Phase 1 Completed 28 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of Singulair (10 mg) and Xyzal (5 mg) in free combination and fixed-dose combination as HCP1102

Timeline

Start
2012-07
Primary completion
2012-09
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1102 Unknown 5 mg
Subject HCP1102 Unknown 10 mg
Subject Levocetirizine Unknown 5 mg
Subject Montelukast Other / unclassified 10 mg

Indications